Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: Insight from an intravascular ultrasound analysis

Journal of Cardiovascular Medicine

Volumn 10, Issue 3, 2009, Pages 231-237

  Clementi, Fabrizio ^a   Di Luozzo, Marco ^a   Mango, Ruggiero ^c   Luciani, Giulio ^a   Trivisonno, Antonio ^d   Pizzuto, Francesco ^a   Martuscelli, Eugenio ^a   Mehta, Jawahar L ^b   Romeo, Francesco ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d OSPEDALI RIUNITI   (Italy)

Author keywords

Atherosclerosis regression; Atorvastatin; Intravascular ultrasound; Pioglitazone

Indexed keywords

ATORVASTATIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DETERIORATION; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFECT; EXERCISE TEST; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART STRESS; HUMAN; HYPERGLYCEMIA; INTRAVASCULAR ULTRASOUND; MALE; MONOTHERAPY; NECROSIS; OUTCOME ASSESSMENT; TREATMENT DURATION; CALCINOSIS; COMPUTER INTERFACE; DRUG COMBINATION; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; FIBROSIS; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; REGISTER; TIME; TREATMENT OUTCOME;

AGED; CALCINOSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; FEMALE; FIBROSIS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NECROSIS; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRROLES; REGISTRIES; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL; USER-COMPUTER INTERFACE;

EID: 63049096412     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283212eb6     Document Type: Article

References (52)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234. (Pubitemid 28350165)
2. Mazzone T. Reducing cardiovascular disease in patients with diabetes mellitus. Curr Opin Cardiol 2005; 20:245-249. (Pubitemid 40896359)
3. Mazzone T. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance. Am J Cardiol 2004; 93 (Suppl):27C-31C. (Pubitemid 38721318)
4. Sowers JR. Treatment of hypertension in patients with diabetes. Arch Intern Med 2004; 164:1850-1857.
5. Blood pressure lowering treatment trialists. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410-1419.
6. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and nondiabetic patients: meta-analysis of randomised controlled trials. BMJ 2006; 332:1115-1124. (Pubitemid 44480873)
7. Nathan DM. Finding new treatments for diabetes - how many, how fast . . . how good? N Engl J Med 2007; 356:437-440.
8. Hsueh WA, Law RE. PPARg and atherosclerosis: effects on cell growth movement. Arterioscler Thromb Vasc Biol 2001; 21:1891-1895. (Pubitemid 34219737)
9. Blaschke F, Spanheimer R, Khan M, Law R. Vascular effects of TZDs: new implications. Vascul Pharmacol 2006; 45:3-18. (Pubitemid 43963481)
10. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26:2493-2499. (Pubitemid 37055444)
11. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in nondiabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42:1757-1763. (Pubitemid 37433654)
12. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24:930-934. (Pubitemid 38620874)
13. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor g ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106:523-531. (Pubitemid 30666385)
14. Chen Z, Ishibashi S, Perrey S, Osuga Ji, Gotoda T, Kitamine T, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001; 21:372-377. (Pubitemid 32199118)
15. Li D, Mehta JL. Oxidized LDL, a critical factor in atherogenesis. Cardiovasc Res 2005; 68:353-354.
16. Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 2006; 291:H1738-H1745. (Pubitemid 44497679)
17. Brown BG, Bolson E, Frimer M, Dodge HT. Quantitative coronary arteriography: estimation of dimensions, hemodynamic resistance, and atheroma mass of coronary artery lesions using the arteriogram and digital computation. Circulation 1977; 55:329-337. (Pubitemid 8031071)
18. Brown BG, Hillger LA, Lewis C, Zhao XQ, Sacco D, Bisson B, Fisher L. A maximum-confidence approach for measuring progression and regression of coronary artery disease in clinical trials. Circulation 1993; 87 (Suppl II): II-66-II-73. (Pubitemid 23068574)
19. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987-1993. Am J Epidemiol 1997; 146:483-494.
20. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-3517.
21. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005; 46:106-112. (Pubitemid 40905137)
22. Kasaoka S, Tobis JM, Akiyama T, Reimers B, Di Mario C, Wong ND, Colombo A. Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol 1998; 32:1630-1635. (Pubitemid 28545201)
23. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al., REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering on progression of coronary atherosclerosis. JAMA 2004; 291:1071-1080.
24. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al., CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292:2217-2225.
25. Virmani R, Kolodgie FD, Burke A, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions arteriosclerosis. Thromb Vasc Biol 2000; 20:1262. (Pubitemid 30262927)
26. Dandapat A, Hu CP, Chen J, Liu Y, Junaid A, Khan JA, et al. Over-expression of angiotensin II type 2 receptor (agtr2) decreases collagen accumulation in atherosclerotic plaque. Biochem Biophys Res Commun 2008; 366:871-877.
27. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30:S42-S47.
28. Kendrach MG. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother 2004; 38:1286-1292.
29. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, et al. American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2007; 30:S48-S56.
30. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002; 106:2200-2206. (Pubitemid 35222213)
31. Rodriguez-Granillo GA, Aoki J, Ong ATL, Valgimigli M, Van Mieghem CA, Regar E, et al. Methodological considerations and approach to crosstechnique comparisons using in vivo coronary plaque characterization based on intravascular radiofrequency data anlaysis: insights from the integrated Biomarker and Imaging Study (IBIS). Int J Cardiovasc Intervent 2005; 7:52-58. (Pubitemid 40780429)
32. Kåresen K. Deconvolution of sparse spike trains by iterated window maximization. IEEE Trans Signal Proc 1997; 45:1173-1183.
33. Kaaresen KF, Bolviken E. Blind deconvolution of ultrasonic traces accounting for pulse variance. IEEE Trans Ultrason Ferroelectr Freq Control 1999; 46:564-573.
34. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al., for the ASTEROID Investigators. ASTEROID Investigators effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556-1565.
35. Dormandy JA, Charbonnel B, Eckland JA, Erdmann E, Massi-Benedetti M, Moules IK, et al., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
36. Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997; 30:569-575. (Pubitemid 27339340)
37. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al., PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299:1561-1573.
38. Sugamura K, Sugiyama S, Matsuzawa Y, Nozaki T, Horibata Y, Ogawa H. Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease. Circ J 2008; 72:1193-1197. (Pubitemid 351957091)
39. Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, Sakamoto T, et al. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in nondiabetic men. Circ J 2007; 71:1703-1709. (Pubitemid 350240089)
40. Komura N, Kihara S, Sonoda M, Kumada M, Fujita K, Hiuge A, et al. Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease. Circ J 2008; 72:23-28.
41. von Eynatten M, Humpert PM, Bluemm A, Lepper PM, Hamann A, Allolio B, et al. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis 2008; 199:123-128. (Pubitemid 351842696)
42. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296:2572-2581. (Pubitemid 44903861)
43. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 2007; 298:1180-1188. (Pubitemid 47403104)
44. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471. (Pubitemid 46919772)
45. Hsiao A, Worrall DS, Olefsky JM, Subramaniam S. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 2004; 20:3108-3127. (Pubitemid 39619201)
46. Hetzel J, Balletshofer B, Rittig K. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005; 25:1804-1809. (Pubitemid 41243446)
47. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endotheliumdependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006; 113:867-875. (Pubitemid 43754309)
48. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679-684. (Pubitemid 34851926)
49. Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26:182-188. (Pubitemid 43732247)
50. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89:4312-4319. (Pubitemid 39244431)
51. Goldberg RB, Kendall DM, DeegMA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28:1547-1554. (Pubitemid 40923063)
52. Rodriguez-Granillo GA, Vaina S, Garcia-Garcia HM, Valgimigli M. Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for the design of longitudinal studies. Int J Cardiovasc Imaging 2006; 22:621-631.